Reverse Splits Scam

[Rosym]

Amarantus BioScience (AMBS) is aiming to be first to market with an accurate, reliable and commercially- viable diagnostic blood test for Alzheimer's disease.

Data gives them all the information they need to move full steam ahead with this strategy. They can now tailor their initial marketing efforts towards the $150M RUO market, primarily targeting pharmaceutical companies engaged in Alzheimer's disease therapeutic trials. They have nearly completed assembling the resources needed to launch LymPro to the RUO community. Thereafter, they intend to market LymPro to the broader medical community, initially under CLIA. We estimate the worldwide market for an Alzheimer's diagnostic is $3B

I really believe AMBS will be huge!